Avrobio Collaborates with Magenta Therapeutics for Advancing Novel ADC
Avrobio Inc. (AVRO) announced its latest collaboration with Magenta Therapeutics (MGTA) for advancing the latter's lead drug candidate MGTA-117. The tie-up will provide synergies for both the companies as Avrobio provides its expertise in lentiviral gene therapies while Magenta offers proficiency in ADC-based conditioning. The companies will jointly assess MGTA-117 in conjunction with one or more of Avrobio's investigational gene therapies.
MGTA-117 is a CD117-targeted antibody engineered for the transplant setting and is conjugated to amanitin. The drug candidate aims to specifically